ALSO NOTED: Tarceva gets Japan's nod; FDA blesses Novartis arthritis remedy;

> Japanese drug regulators approved Roche's lung cancer drug Tarceva, made by OSI Pharmaceuticals. Release

> The FDA has given its blessing to Novartis' Voltaren, a topical non-steroidal anti-inflammatory gel for relief of osteoarthritis pain; systemic absorption is 94 percent less than with oral NSAID formulations, the company said. Release

> Solvay has inked a deal with Abbott Laboratories to jointly promote Abbott's combination cholesterol drug Simcor, which puts simvastatin and Niaspan in one pill. Release

> In a major setback for Dor BioPharma, the FDA has issued a not approvable letter for the company's lead drug orBec, a treatment for gastrointestinal Graft-versus-Host disease (GI GVHD). Report

> Ranbaxy, one of India's largest drug makers and a dominant force in the generic drugs business, is spinning off its R&D unit that will develop new medicines. Report

And Finally... Cancer death rates, part II: They're down overall, but certain cancers, such as myeloma, are on the uptick. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.